Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

If a new experiment pans out, Medicaid and Medicare could begin covering the costly weight-loss drugs that price out many ...

Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line to face price negotiations between manufacturers and Medicare. The Biden administration released the first 10 ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...